Aeras, OETC commence TB drug Phase IIb trial
The trial will evaluate the HIV patients who are using MVA85A, which is being developed by OETC, a joint venture between the University of Oxford and Emergent BioSolutions,
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.